Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1347-1356

  Foureau, David M ^a   McKillop, Iain H ^a   Jones, Chase P ^a   Amin, Asim ^a   White, Richard L ^a   Salo, Jonathan C ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

CD8 T cells; Foxp3; Interleukin 2; Melanoma

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HERMES ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD8+ FOXP3+ T LYMPHOCYTE; CELL EXPANSION; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FIBROSARCOMA; IMMUNOCOMPETENCE; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPH NODE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; T LYMPHOCYTE SUBPOPULATION; TUMOR MODEL;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOCOMPETENCE; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 80054713368     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1035-1     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Yang AS, Chapman PB (2009) The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 23:583-597
3. Atkins MB, LotzeMT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116 (Pubitemid 29318842)
4. Riker AI, Radfar S, Liu S, Wang Y, Khong HT (2007) Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7:345-358 (Pubitemid 46383477)
5. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-1977 (Pubitemid 23304623)
6. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869-875 (Pubitemid 350002888)
7. Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3
8. Malek TR (2008) The biology of interleukin-2. Annu Rev Immunol 26:453-479 (Pubitemid 351600382)
9. Waldmann TA, Dubois S, Tagaya Y (2001) Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14:105-110 (Pubitemid 32206513)
10. Ahmadzadeh M, Antony PA, Rosenberg SA (2007) IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 30:294-302 (Pubitemid 46586645)
11. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL et al (2006) Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103:6659-6664
12. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4 ? CD25? regulatory T cells. Nat Immunol 4:330-336 (Pubitemid 36432314)
13. Wildin RS, Smyk-Pearson S, Filipovich AH (2002) Clinical and molecular features of the immuno dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39:537-545 (Pubitemid 34864555)
14. Torgerson TR, Ochs HD (2007) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forehead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 120:744-750 (quiz 751-742) (Pubitemid 47531861)
15. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148-149
16. Nakayama J, Urabe K, Tsuchida T, Urabe A, Terao H, Taniguchi S, Hori Y (1995) Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides. J Dermatol 22:549-559
17. Berkelhammer J, Luethans TN, Hook RR Jr, Oxenhandler RW (1986) Phenotypic instability of mouse melanomas after propagation in vivo and in vitro. Cancer Res 46:2923-2928 (Pubitemid 16074306)
18. Rosenberg SA, Schwarz SL, Spiess PJ (1988) Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80:1393-1397
19. Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NS (2001) CD8 ? CD28- T suppressor cells and the induction of antigenspecific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 182:201-206 (Pubitemid 33070219)
20. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA et al (2008) T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 105:7797-7802 (Pubitemid 351872718)
21. Mayer CT, Floess S, Baru AM, Lahl K, Huehn J, Sparwasser T (2011) CD8 ? Foxp3? T cells share developmental and phenotypic features with classical CD4 ? Foxp3 ? regulatory T cells but lack potent suppressive activity. Eur J Immunol 41:716-725
22. Dutton RW, Bradley LM, Swain SL (1998) T cell memory. Annu Rev Immunol 16:201-223 (Pubitemid 28183364)
23. Suciu-Foca N, Berloco P, Cortesini R (2009) Tolerogenic dendritic cells in cancer, transplantation, and autoimmune diseases. Hum Immunol 70:277-280
24. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL et al (2004) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-290 (Pubitemid 39071633)
25. Faunce DE, Terajewicz A, Stein-Streilein J (2004) Cutting edge: in vitro-generated tolerogenic APC induce CD8 ? T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol 172:1991-1995 (Pubitemid 38182341)